Renowned Speakers
Ken Ware
NeuroPhysics Therapy Institute and Research Centre Australia
Dr. Ulrich Wesemann
Royal Bahrain hospital Germany
Lisa Feldman-Barrett
University Distinguished Professor of Psychology at Northeastern USA
Ekaterina Zubrickaya
Krasnoyarsk State Medical University Russia
Meijuan Lu
President of Meng River Chinese Medicine Research Co. Ltd, USA
Hossein Ansari
Board-Certified Neurologist And Certified Headache Specialist UC San Diego Health San Diego, California USA
James-Gratwicke
The National Hospital for Neurology and Neurosurgery UK
Recommended Global Neuroscience Webinars & Conferences
Asia Pacific & Middle East
Canada
Neurogenetics 2027
About Conference
- Lectures and presentations from renowned researchers and clinicians
- Keynote sessions by prominent professors and healthcare professionals
- Oral and poster presentations
- Discussions on emerging developments in neuroscience and neurogenetics
- Sessions on neurological disorders and genetic conditions
- Insights into innovative diagnostic and therapeutic approaches
- Opportunities for international networking and collaboration
- Knowledge exchange among researchers, academics, clinicians, and industry professionals
- Opportunities to present research and share scientific findings
- Discussions on future directions in neurological research and patient care
- Neurologists
- Neurosurgeons
- Neuroscientists
- Neurogeneticists
- Neuropsychologists
- Neurophysiologists
- Geneticists
- Biotechnology professionals
- University professors and academics
- Medical researchers
- Neurochemists
- Neuromuscular specialists
- Healthcare professionals
- Pharmacists
- Pharmaceutical and biotechnology companies
- Drug discovery and development professionals
- Medical students
- Research scholars
- Neurology organizations and societies
- Neuroscience associations and foundations
- Professionals involved in neurological research and clinical care
Sessions And Tracks
Track 1: Genetics and Neurogenetics
This track focuses on molecular genetics, genetic variations, inherited neurological disorders, genotype–phenotype correlations, genetic mechanisms of neurological diseases, and advances in neurogenetic research.
Track 2: Neurodegeneration and Dementia
This track covers Alzheimer’s and Parkinson’s diseases, neurodegenerative disorders, dementia, cognitive decline, brain aging, neuronal dysfunction, and emerging therapeutic approaches.
Track 3: Neuroimmunology and Neuroinfection
This track focuses on neuroinflammation, immune-mediated neurological disorders, multiple sclerosis, autoimmune neuropathies, neurovirology, neuroinfectious diseases, and novel treatment strategies.
Track 4: Neurological Diagnostics and Neuroimaging
This track covers neurological examination, MRI, CT, PET, brain imaging, angiography, diagnostic procedures, and emerging technologies for the diagnosis and monitoring of neurological disorders.
Track 5: Neurorehabilitation and Genetic Counseling
This track focuses on neurological rehabilitation, occupational rehabilitation, rehabilitation for neurogenetic disorders, genetic counseling, risk assessment, and patient-centered neurological care.
Track 6: Neuropharmacology and Therapeutics
This track covers CNS receptors, neuropharmacology, drug development, therapeutic targets, neuroprotective treatments, clinical trials, and emerging pharmacological approaches for neurological disorders.
Track 7: Pediatric Neurology and Neurodevelopment
This track focuses on pediatric neurogenetic disorders, neurodevelopmental disorders, genetic and chromosomal conditions, perinatal neurology, neonatal neurological disorders, and child neurological health.
Track 8: Neuro-Ophthalmology
This track covers neurological causes of visual dysfunction, optic nerve disorders, neuro-ophthalmic manifestations, neurological eye disorders, and advances in diagnosis and treatment.
Track 9: Neuro-Oncology and Neuropathology
This track focuses on brain and spinal cord tumors, primary and metastatic nervous system tumors, molecular neuro-oncology, neuropathology, neurocytology, tissue pathology, and neuromuscular disorders.
Track 10: Stroke, Neurocardiology and Neurovascular Disorders
This track covers stroke mechanisms and management, neurovascular disorders, neurocardiac interactions, the heart–brain axis, arrhythmias, autonomic regulation, and advances in stroke care.
Track 11: Neurochemistry and Molecular Neuroscience
This track focuses on neurotransmitters, neuropeptides, molecular neuroscience, chemical neurobiology, neuroinflammation, immunoneurochemistry, neural signaling, and molecular mechanisms of the nervous system.
Track 12: Nursing, Neuroscience and Patient Care
This track covers neurological nursing, neurotrauma, neurosurgical nursing, neurological intensive care, long-term neurological conditions, rehabilitation support, and patient-centered neurological care.
Track 13: Ataxia, Epilepsy and Movement Disorders
This track focuses on cerebellar and genetic ataxia, epilepsy and seizure disorders, movement disorders, their causes, diagnosis, clinical management, and emerging treatment approaches.
Track 14: Psychiatry, Psychology and Behavioral Neuroscience
This track covers neuropsychiatry, behavioral neuroscience, clinical psychology, mental health, psychotherapy, cognitive and behavioral disorders, and the neurobiological aspects of psychiatric conditions.
Track 15: Emerging Technologies and Translational Neuroscience
This track focuses on next-generation sequencing, genome-wide studies, recombinant DNA technologies, advanced genetic analysis, translational research, clinical trials, emerging diagnostic technologies, and innovative therapeutic approaches in neuroscience.
Market Analysis
The 38th Conference on Clinical Neuroscience and Neurogenetics, taking place on March 24–25, 2027, in Geneva, Switzerland, focuses on the growing field of neuroscience and neurogenetics under the theme “Transforming Neurological Care Through Neuroscience, Genetics, and Innovation.”
The conference addresses key areas including neurogenetics, neurodegeneration, neuroimmunology, diagnostic tools, neuropharmacology, pediatric neurology, neuro-ophthalmology, neuro-oncology, neuropathology, neurocardiology and neuroimaging, neurochemistry, and neurogenetic research.
The neurodegenerative disease sector continues to receive significant research attention due to the growing aging population and increasing prevalence of neurological disorders. The provided data identifies Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and ALS among important neurodegenerative conditions and highlights the continuing need for effective diagnostic and therapeutic approaches.
Key Market Drivers
-
Growing prevalence of neurological and neurodegenerative disorders
-
Increasing aging population and associated neurological conditions
-
Advances in neurogenetic and molecular research
-
Demand for improved diagnostic tools and imaging technologies
-
Development of innovative drugs and therapeutic approaches
-
Rising international collaboration in neuroscience and neurology
Neurogenetics | Neurodegeneration | Neuroimmunology | Diagnostics | Neuropharmacology | Pediatric Neurology | Neuro-Oncology | Neuroimaging | Neurocardiology | Neurochemistry | Genetic Research
The conference will provide a platform for researchers, clinicians, neurologists, geneticists, and healthcare professionals to exchange knowledge and discuss emerging developments across these rapidly advancing fields.
Neurodegenerative diseases are related to neurons present in human brain. The global neurodegenerative disease market is expected to rise at a CAGR of 4.90% during the forecast period 2016-2023. The major driver of the global neurodegenerative disease market is rising aging population globally. According to the National Institute on Aging, 6.5 million people aged 65 years and above globally. The worldwide population of the oldest people of age 80 and above is anticipated to rise by thrice that is from 126.5 million to 446.6 million during 2015 to 2050.
Since the nature of the neurodegenerative diseases is complex, there are many factors that prompt the growth of the global neurodegenerative disease market. Some of the key factors include the rapid growth of neurodegenerative diseases across the globe and raising awareness about mental disorders. The rising geriatric population across the world increases the chances of occurrence of neurological diseases. Researchers are being conducted to find an effective treatment for neurodegenerative diseases can fuel the growth of this market. The major restraining factor of the global neurodegenerative disease market is the lack of effective drugs and therapies to treat the disease. Also, the lack of information about the causes of these neurodegenerative diseases hinders the development of drugs and treatment for the same.
With the advanced aging of the ‘baby boom’ generation in many Western countries, age-related neurodegenerative disorders like dementia and Parkinson’s disease (PD) are becoming a major healthcare problem. Approximately 10% of adults above 65 years and 47% of adults above 85 years suffer from dementia, 1–3% of the population above 60 years currently suffers from PD, while (partly) genetically determined neurodegenerative disorders like Huntington’s chorea or amyotrophic lateral sclerosis (ALS) affect a considerable number of subject.
In Switzerland, 8% of Neuro researchers are going. In the USA 11% of Neuro research is going.
To Collaborate Scientific Professionals around the World
Conference Date March 24-25, 2027
For Sponsors & Exhibitors
Speaker Opportunity
Useful Links
Past Conference Report
Supported By
All accepted abstracts will be published in respective Conference Series International Journals.
Abstracts will be provided with Digital Object Identifier by
